Lupin Collaborates with ERN for Luforbec (beclometasone/formoterol) pMDI Launch in Spain.
Lupin Receives Approval from U.S. FDA for Ranluspec (Ranibizumab) Injection
Intimation of allotment of 16673 equity shares under ESOP.
Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection.
Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets.
Update on acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc.
Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026.
Lupin's Ankleshwar Facility Receives EIR from U.S. FDA.
Intimation about participating in the Analyst/Institutional Investors Meet.
Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension.
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 3,495.64 | 3,659.23 | 4,115.75 | 3,395.88 | 4,167.63 | 4,106.20 | 4,208.00 | 4,485.67 | 5,708.59 | 4,068.28 | 4,501.19 | 5,234.60 |
| YOY Revenue Growth % | 27.93% | 29.35% | 43.85% | 19.73% | 19.22% | 12.21% | 2.24% | 32.09% | 36.97% | -0.92% | 6.97% | 16.7% |
| Other Income | 27.74 | 25.60 | 23.16 | 31.34 | 38.22 | 32.62 | 55.30 | 48.79 | 54.14 | 70.00 | 99.80 | 88.83 |
| Total Income | 3,523.38 | 3,684.83 | 4,138.91 | 3,427.22 | 4,205.85 | 4,138.82 | 4,263.30 | 4,534.46 | 5,762.73 | 4,138.28 | 4,600.99 | 5,323.43 |
| Total Expenses + | 2,946.85 | 2,988.79 | 3,054.95 | 2,999.06 | 3,122.93 | 3,154.77 | 2,969.02 | 2,981.37 | 3,174.58 | 3,095.15 | 3,099.21 | 3,168.81 |
| Cost of Materials Consumed | 829.64 | 855.88 | 836.97 | 884.81 | 973.30 | 907.04 | 912.78 | 923.60 | 909.14 | 864.14 | 909.55 | 995.53 |
| Employee Benefit Expense | 523.79 | 532.18 | 522.47 | 517.07 | 588.77 | 594.51 | 576.37 | 552.42 | 643.89 | 608.83 | 631.51 | 660.65 |
| Other Expenses | 1,020.48 | 1,065.40 | 1,042.03 | 959.90 | 1,114.96 | 1,067.72 | 1,064.50 | 1,011.43 | 1,153.74 | 1,014.56 | 1,064.84 | 1,055.74 |
| Operating Profit | 548.79 | 670.44 | 1,060.80 | 396.82 | 1,044.70 | 951.43 | 1,238.98 | 1,504.30 | 2,534.01 | 973.13 | 1,401.98 | 2,065.79 |
| OPM % | 15.7% | 18.3% | 25.8% | 11.7% | 25.1% | 23.2% | 29.4% | 33.5% | 44.4% | 23.9% | 31.1% | 39.5% |
| Profit Before Tax + | 576.53 | 696.04 | 1,083.96 | 428.16 | 1,082.92 | 984.05 | 1,217.06 | 1,553.09 | 2,588.15 | 1,635.81 | 867.94 | 2,602.35 |
| Tax Expense | 99.57 | 147.43 | 167.52 | 44.08 | 193.74 | 176.29 | 232.39 | 261.74 | 460.08 | 278.46 | 150.49 | 438.66 |
| Tax % | 17.3% | 21.2% | 15.5% | 10.3% | 17.9% | 17.9% | 19.1% | 16.9% | 17.8% | 17% | 17.3% | 16.9% |
| Profit After Tax | 476.96 | 548.61 | 916.44 | 384.08 | 889.18 | 807.76 | 984.67 | 1,291.35 | 2,128.07 | 1,357.35 | 717.45 | 2,163.69 |
| EPS (Basic) | 10.48 | 12.06 | 20.14 | 8.43 | 19.51 | 17.71 | 21.58 | 28.30 | 46.60 | 29.72 | 15.71 | 47.35 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 19,512.66 | 16,967.50 | 14,666.50 | 11,258.83 | 11,771.67 | 11,055.93 | 11,025.66 |
| YOY Revenue Growth % | 15% | 15.69% | 30.27% | -4.36% | 6.47% | 0.27% | - |
| Other Income | 312.77 | 174.05 | 106.73 | 91.26 | 150.42 | 129.09 | 475.19 |
| Total Income | 19,825.43 | 17,141.55 | 14,773.23 | 11,350.09 | 11,922.09 | 11,185.02 | 11,500.85 |
| Total Expenses + | 12,537.75 | 12,227.21 | 11,988.54 | 10,822.95 | 12,083.62 | 9,555.32 | 7,664.00 |
| Cost of Materials Consumed | 3,678.36 | 3,716.72 | 3,407.30 | 3,151.20 | 2,816.90 | 2,741.22 | 2,753.22 |
| Employee Benefit Expense | 2,544.88 | 2,312.07 | 2,095.51 | 1,934.14 | 1,918.16 | 1,695.86 | 1,703.22 |
| Other Expenses | 4,288.88 | 4,257.73 | 4,086.70 | 3,444.34 | 5,110.54 | 3,133.70 | 3,207.56 |
| Operating Profit | 6,974.91 | 4,740.29 | 2,677.96 | 435.88 | -311.95 | 1,500.61 | 3,361.66 |
| OPM % | 35.7% | 27.9% | 18.3% | 3.9% | -2.7% | 13.6% | 30.5% |
| Profit Before Exceptional | 7,287.68 | 4,914.34 | 2,784.69 | 527.14 | -161.53 | 1,629.70 | 1,811.46 |
| Exceptional Items | 406.57 | -77.22 | 0.00 | 0.00 | 0.00 | 0.00 | -759.21 |
| Profit Before Tax + | 7,694.25 | 4,837.12 | 2,784.69 | 527.14 | -161.53 | 1,629.70 | 1,052.25 |
| Tax Expense | 1,327.69 | 864.16 | 458.60 | 101.93 | 27.17 | 371.08 | 324.70 |
| Tax % | 17.3% | 17.9% | 16.5% | 19.3% | - | 22.8% | 30.9% |
| Profit After Tax | 6,366.56 | 3,972.96 | 2,326.09 | 425.21 | -188.70 | 1,258.62 | 727.55 |
| EPS (Basic) | 139.38 | 87.10 | 51.10 | 9.35 | -4.16 | 27.77 | 16.07 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Non-Current Assets + | 20,507.83 | 16,537.44 | 15,634.99 | 15,112.75 | 13,875.55 | 12,241.19 | 0.00 |
| Property, Plant & Equipment | 3,168.51 | 3,445.67 | 3,498.22 | 3,677.82 | 3,617.55 | 3,556.17 | 0.00 |
| Capital Work in Progress | 429.43 | 231.90 | 411.12 | 737.99 | 773.74 | 795.83 | 0.00 |
| Non-Current Investments | 12,200.55 | 10,951.47 | 10,771.82 | 9,534.56 | 8,688.69 | 7,241.59 | 0.00 |
| Goodwill | 0.00 | 0.00 | 15.86 | 15.86 | 0.00 | 0.00 | 0.00 |
| Other Intangible Assets | 1,076.73 | 1,155.45 | 599.09 | 328.25 | 72.63 | 82.66 | 0.00 |
| Current Assets + | 15,595.06 | 11,894.55 | 9,140.18 | 7,570.92 | 8,437.82 | 9,617.37 | 0.00 |
| Inventories | 3,350.78 | 3,227.22 | 2,969.31 | 3,019.47 | 3,177.14 | 2,708.19 | 0.00 |
| Trade Receivables | 6,922.03 | 5,664.35 | 3,842.15 | 2,674.42 | 2,722.01 | 3,190.54 | 0.00 |
| Cash and Cash Equivalents | 111.63 | 341.80 | 123.70 | 85.66 | 59.10 | 177.41 | 0.00 |
| Current Investments | 1,000.00 | 1,000.00 | 808.85 | 439.77 | 822.40 | 1,000.00 | 0.00 |
| LIABILITIES & EQUITY | |||||||
| Total Equity | 30,133.77 | 24,278.24 | 20,603.09 | 18,411.86 | 18,150.19 | 18,565.57 | 0.00 |
| Equity Share Capital | 91.44 | 91.32 | 91.14 | 91.00 | 90.90 | 90.74 | 0.00 |
| Other Equity | 30,042.33 | 24,186.92 | 20,511.95 | 18,320.86 | 18,059.29 | 18,474.83 | 0.00 |
| Non-Current Liabilities | 1,136.79 | 854.01 | 625.83 | 643.96 | 625.27 | 707.16 | 0.00 |
| Current Liabilities | 4,832.33 | 3,232.52 | 3,646.42 | 3,627.85 | 3,537.91 | 2,585.83 | 0.00 |
| Total Liabilities | 5,969.12 | 4,153.75 | 4,319.77 | 4,271.81 | 4,163.18 | 3,292.99 | 0.00 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activities | 5,539.85 | 2,444.65 | 2,504.91 | 1,784.55 | 252.17 | 0.00 | 0.00 |
| Cash from Investing Activities | -5,648.89 | -1,766.32 | -1,599.80 | -1,259.73 | -472.93 | 0.00 | 0.00 |
| Cash from Financing Activities | -121.13 | -460.23 | -867.07 | -498.26 | 102.45 | 0.00 | 0.00 |
| Net Increase/Decrease in Cash | -230.17 | 218.10 | 38.04 | 26.56 | -118.31 | 0.00 | 0.00 |